10 results on '"Danzon, Arlette"'
Number of results to display per page
Search Results
2. Incidence and survival of gastric non-Hodgkin's lymphoma: A population-based study from the Association of the French Cancer Registries (FRANCIM)
- Author
-
Danzon, Arlette, Belot, Aurélien, Maynadié, Marc, Remontet, Laurent, Dupont, Anne Claire Gossart, Carbonnel, Franck, Renseigné, Non, FRANCIM, Réseau des registres français du cancer, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Service de Biostatistique, Hospices Civils de Lyon (HCL), Biostatistiques santé, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Département des maladies chroniques et traumatismes, Institut de Veille Sanitaire (INVS), Registre des hémopathies malignes de Côte d'Or, Service de biostatistique, Agents pathogènes et inflammation - UFC (EA 4266) (API), Université de Franche-Comté (UFC), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Hospices Civils de Lyon ( HCL ), Laboratoire de Biométrie et Biologie Evolutive ( LBBE ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique ( Inria ) -Centre National de la Recherche Scientifique ( CNRS ), Agents pathogènes et inflammation - UFC (EA 4266) ( API ), and Université de Franche-Comté ( UFC )
- Subjects
Male ,Multivariate analysis ,MESH: Registries ,MESH : Age Distribution ,MESH : Aged ,0302 clinical medicine ,MESH: Lymphoma, Non-Hodgkin ,Risk Factors ,MESH: Risk Factors ,Epidemiology ,MESH : Stomach Neoplasms ,MESH : Neoplasm Staging ,MESH : Female ,Registries ,MESH: Incidence ,030212 general & internal medicine ,Age of Onset ,MESH : Sex Distribution ,MESH: Aged ,MESH : Prognosis ,MESH: Middle Aged ,Relative survival ,Incidence ,Lymphoma, Non-Hodgkin ,Incidence (epidemiology) ,MESH: Sex Distribution ,Not Otherwise Specified ,MESH: Stomach Neoplasms ,MESH: Neoplasm Staging ,Hematology ,General Medicine ,Middle Aged ,MESH : Adult ,Prognosis ,MESH : Risk Factors ,MESH : Incidence ,MESH : Age of Onset ,3. Good health ,Oncology ,MESH: Young Adult ,MESH: Survival Analysis ,030220 oncology & carcinogenesis ,Female ,[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology ,France ,Adult ,medicine.medical_specialty ,Adolescent ,MESH : Male ,MESH: Age of Onset ,MESH : Young Adult ,MESH: Multivariate Analysis ,MESH: Prognosis ,Young Adult ,03 medical and health sciences ,Age Distribution ,Stomach Neoplasms ,MESH : Adolescent ,Internal medicine ,medicine ,Humans ,MESH : Middle Aged ,MESH : Lymphoma, Non-Hodgkin ,Radiology, Nuclear Medicine and imaging ,Sex Distribution ,MESH : France ,MESH: Age Distribution ,Survival analysis ,Aged ,Neoplasm Staging ,MESH: Adolescent ,MESH: Humans ,business.industry ,MESH : Humans ,MESH : Multivariate Analysis ,Cancer ,MESH: Adult ,[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology ,medicine.disease ,Survival Analysis ,MESH: Male ,MESH: France ,Multivariate Analysis ,Immunology ,MESH : Survival Analysis ,Age of onset ,business ,MESH: Female ,MESH : Registries - Abstract
International audience; BACKGROUND: Most epidemiological studies on gastric lymphomas (GL) were carried out before changes in therapy were introduced. The aim of the study was to measure the incidence of GL and to estimate survival. MATERIAL AND METHODS: Data were provided by the Association of the French Cancer Registries database. Age-standardized incidence rates were calculated for 786 incident cases diagnosed between 1978 and 2002. Crude and relative survival were calculated for 361 cases diagnosed between 1989 and 1997. Effects specific to sex, age at diagnosis, year of diagnosis, and grade of malignancy were estimated in multivariate analysis. RESULTS: Incidence was stable during the study period. However, high-grade GL frequency increased whereas low-grade and not otherwise specified (NOS) GL frequencies were respectively stable and decreased. At 5 years, relative survival was 63% in men and 60% in women. Patients aged 75 or older had a five-year relative survival of 33%. Age at diagnosis was the only significant prognostic factor in multivariate analysis. Time trend improvement in prognosis was observed. DISCUSSION: Results in elderly patients show that therapeutic regimens should be specifically designed and assessed for them. The prognosis improvement trend is probably related to the implementation of changes in management of patients and has to be confirmed by more recent data.
- Published
- 2009
3. Evolution of pleural cancers and malignant pleural mesothelioma incidence in France between 1980 and 2005
- Author
-
Le Stang, Nolwenn, Belot, Aurélien, Gilg Soit Ilg, Anabelle, Rolland, P., Astoul, Philippe, Bara, Simona, Brochard, Patrick, Danzon, Arlette, Delafosse, Patricia, Grosclaude, Pascale, Guizard, Anne-Valérie, Imbernon, Ellen, Lapôtre-Ledoux, Bénédicte, Ligier, Karine, Molinié, Florence, Pairon, Jean-Claude, Sauleau, Erik-André, Trétarre, Brigitte, Velten, Michel, Bossard, Nadine, Goldberg, Marcel, Launoy, Guy, Galateau-Sallé, Françoise, Launoy, Guy, Registre multicentrique à vocation nationale des mésothéliomes pleuraux, Registre Multicentrique à Vocation Nationale des Mésothéliomes Pleuraux (MESONAT), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Cancers et Populations : Facteurs de Risque, Depistage, Pratiques Diagnostiques et Therapeutiques, Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Biostatistique, Hospices Civils de Lyon (HCL), Biostatistiques santé, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Département des maladies chroniques et traumatismes, Institut de Veille Sanitaire (INVS), Département santé travail (DST-InVS), Division d'oncologie thoracique, Département des maladies pulmonaires, Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), FRANCIM, Réseau des registres français du cancer, Laboratoire Santé Travail Environnement, Université Bordeaux Segalen - Bordeaux 2-IFR99, Service de Médecine du Travail et de Pathologies Professionnelles, CHU Bordeaux [Bordeaux], Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service de pneumologie et pathologie professionnelle, CHI Créteil, Center for Neurologic Diseases, and Brigham and Women's Hospital [Boston]
- Subjects
Male ,Mesothelioma ,[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie ,Incidence ,Pleural Neoplasms ,Humans ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,Female ,France ,Registries ,respiratory system ,neoplasms ,respiratory tract diseases - Abstract
International audience; The evolution of pleural cancers and malignant pleural mesothelioma incidence in France between 1980 and 2005 was analysed using data derived from the French network of cancer registries (FRANCIM) and the French National Mesothelioma Surveillance Program (PNSM). Mesothelioma proportions in pleural cancers were calculated by diagnosis year in the 1980-2000 period. Our results suggest that the incidences of pleural cancer and mesothelioma levelled off in French men since 2000 and continued to increase in French women. A decrease of the annual pleural cancer incidence average in men was noticed (-3.4% of annual rate of change) between 2000 and 2005. The proportion of pleural cancers that were mesothelioma was unchanged between 1980 and 2003 with an average of 86%. The age standardised incidence rate of pleural mesothelioma remained relatively stable between 1998 and 2005 with a slight falling trend. For women, the age standardised incidence rate of pleural cancers and mesothelioma increased during the period 1998-2005. Additionally, the proportion of pleural cancers that were mesothelioma increased during the same period of time. Finally, the increased trend observed in the incidence of pleural mesothelioma and cancers in women is credibly due to their under diagnosis in the 1980-1997 period. The comparison between the French incidence and the American and British ones shows that the decreasing trend in incidence of mesothelioma and pleural cancers in French men since 2000 is potentially associated with a lower amphibole consumption and by the implementation of safety regulations at work from 1977. (c) 2009 UICC.
- Published
- 2009
4. Incidence of uveal melanoma in Europe
- Author
-
Virgili , Gianni, Gatta , Gemma, Ciccolallo , Laura, Capocaccia , Riccardo, Biggeri , Annibale, Crocetti , Emanuele, Lutz , Jean-Michel, Paci , Eugenio, Renseigné , Non, Danzon , Arlette, Evaluative Epidemiology Unit, Fondazione IRCCS, Department of Statistics 'G. Parenti', University of Florence and Biostatistics Unit ISPO (Institute for Cancer Prevention and Research), Registre Genevois des Tumeurs, CHU Genève, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Università degli Studi di Firenze = University of Florence [Firenze] (UNIFI), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)
- Subjects
Male ,Uveal Neoplasms ,MESH: Registries ,Climate ,MESH : Age Distribution ,MESH : Aged ,MESH : Child, Preschool ,[ SDV.CAN ] Life Sciences [q-bio]/Cancer ,0302 clinical medicine ,MESH : Child ,MESH: Child ,MESH : Female ,Registries ,MESH: Incidence ,Child ,Melanoma ,MESH : Sex Distribution ,MESH: Aged ,MESH: Middle Aged ,Incidence (epidemiology) ,Incidence ,MESH: Sex Distribution ,MESH : Infant ,Middle Aged ,MESH : Adult ,MESH: Climate ,MESH: Infant ,MESH : Incidence ,3. Good health ,MESH: International Classification of Diseases ,MESH : Uveal Neoplasms ,Europe ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Child, Preschool ,symbols ,Female ,Adult ,medicine.medical_specialty ,Adolescent ,MESH: Melanoma ,MESH : Male ,Ocular Melanoma ,MESH : Europe ,MESH : Melanoma ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,03 medical and health sciences ,symbols.namesake ,Age Distribution ,International Classification of Diseases ,Internal medicine ,MESH : Adolescent ,MESH : International Classification of Diseases ,medicine ,Humans ,MESH : Middle Aged ,Poisson regression ,Sex Distribution ,MESH: Age Distribution ,Aged ,MESH: Adolescent ,MESH: Humans ,business.industry ,MESH: Child, Preschool ,MESH : Humans ,Cancer ,Infant ,MESH: Adult ,MESH : Climate ,medicine.disease ,Confidence interval ,MESH: Male ,Surgery ,Cancer registry ,Ophthalmology ,030221 ophthalmology & optometry ,MESH: Uveal Neoplasms ,Choroid ,MESH: Europe ,business ,MESH: Female ,International Classification of Diseases for Oncology ,MESH : Registries - Abstract
International audience; PURPOSE: To estimate incidence rates of uveal melanoma in Europe from 1983 to 1994. DESIGN: Incidence analysis of data from cancer registries adhering to the European Cancer Registry-based study on survival and care of cancer patients (EUROCARE) (cases diagnosed from 1983 to 1994). PARTICIPANTS: Data of 6673 patients with ocular melanoma (as defined by International Classification of Diseases for Oncology morphology codes 8720 to 8780 [melanoma] and International Classification of Diseases 9 (ICD9) codes 190.0 [iris and ciliary body], 190.5 [retina], 190.6 [choroid], and 190.9 [unspecified ocular location]) from 33 cancer registries of 16 European countries. METHODS: Incidence rate ratios (IRRs) were obtained from a multilevel Poisson regression model. MAIN OUTCOME MEASURES: Incidence rates and IRRs associated with demographic and geographic variables. RESULTS: Standardized incidence rates increased from south to north across registries, from a minimum of 8 per million in Norway and Denmark. The inclusion of tumors with unspecified ocular location (code 190.9) increased incidence rates in most United Kingdom registries, but not in the other geographic areas, where this code was seldom used for uveal melanomas. Incidence increased noticeably up to age 55 (IRR, 1.46 per 5 years; 95% confidence interval [CI], 1.36-1.57) but leveled off after age 75 (IRR, 0.99 per 5 years; 95% CI, 0.93-1.05), with intermediate levels midway (IRR, 1.18 per 5 years; 95% CI, 1.12-1.23). It was also higher in males (IRR, 1.22; 95% CI, 1.16-1.28). Rates were stable during the study period, but a cohort effect was evidenced, accounting for higher incidence rates in people born during the period 1910 to 1935 (P = 0.005). Incidence increased with latitude (P = 0.008), which explained most differences in rates among areas. CONCLUSIONS: In this large series of uveal melanomas, we found stable incidence during the years 1983 to 1994. The north-to-south decreasing gradient supports the protective role of ocular pigmentation. European ophthalmologists should develop guidelines to standardize the coding of tumors treated conservatively using the ICD classification to improve the registration and surveillance of uveal melanoma by cancer registries.
- Published
- 2007
5. [Epidemiology of urogenital cancers in France]
- Author
-
Rébillard, Xavier, Tretarre, Brigitte, Renseigné, Non, Danzon, Arlette, Service d'urologie, Clinique Beausoleil, FRANCIM, Réseau des registres français du cancer, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), and Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC )
- Subjects
MESH: Humans ,Incidence ,MESH : Humans ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Survival Analysis ,MESH : Incidence ,[ SDV.CAN ] Life Sciences [q-bio]/Cancer ,MESH: France ,MESH: Survival Analysis ,Humans ,MESH : Urogenital Neoplasms ,France ,MESH: Incidence ,MESH : Survival Analysis ,MESH : France ,MESH: Urogenital Neoplasms ,Urogenital Neoplasms - Abstract
International audience; Estimates of cancer incidence and mortality in France as well as survival data are published by the cancer registry network (Francim). In 2000, the number of new cancer cases was almost 280,000 in France. This number has been gradually increasing, partly due to population aging. The proportion of urological cancers is increasing as well, as a consequence of the marked increase in number of prostate cancers. The estimated number of new cases for the 4 main urological cancers in 2000 reached 61,174, distributed as follows: 40,310 prostate cancers, 10,771 bladder cancers, 8,293 kidney cancers and 1,800 testis cancers. Urological tumours represented at the time 22% of new cancer cases in France: 35% of male cancers (56,402 /161,025) and 4% of female cancers (4,772/117,228). The relative five-year survival for prostate cancers is high: 80%. It is below that of testis cancers (95% after 5 years), but higher than that of kidney cancers (64% in men and 63% in women after five years). Of all urological cancers, bladder cancers have the worst prognosis, since the relative five-year survival is 60% in men and especially 50% in women.
- Published
- 2007
6. [Incidence and mortality of central nervous system tumors in France: trends over the period 1978-2000 and influence of registration practices on results]
- Author
-
Ménégoz, F., Martin, E., Danzon, Arlette, Mathieu-Daudé, H., Guizard, A.-V., Macé-Lesec'H, J., Raverdy, N., Pasquier, B., Service de Dermatologie, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Institut Fourier ( IF ), Centre National de la Recherche Scientifique ( CNRS ) -Université Grenoble Alpes ( UGA ), Viala, Pascale, Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Hôpital Saint-Jacques, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Université de Franche-Comté (UFC), Institut Fourier (IF), Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques, Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Institut Fourier (IF ), and Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])
- Subjects
Male ,MESH: Survival Rate ,MESH: Registries ,MESH : Retrospective Studies ,MESH : Sex Factors ,MESH : Male ,MESH : Aged ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,MESH : Central Nervous System Neoplasms ,MESH: Central Nervous System Neoplasms ,[ SDV.CAN ] Life Sciences [q-bio]/Cancer ,Central Nervous System Neoplasms ,Sex Factors ,MESH: Sex Factors ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,MESH: Risk Factors ,Risk Factors ,Humans ,MESH : Female ,MESH : Middle Aged ,MESH: Incidence ,Registries ,MESH : France ,Aged ,Retrospective Studies ,MESH: Aged ,MESH: Humans ,MESH: Middle Aged ,Incidence ,MESH : Humans ,MESH: Retrospective Studies ,Middle Aged ,MESH : Survival Rate ,MESH : Risk Factors ,MESH: Male ,MESH : Incidence ,MESH: France ,Survival Rate ,Female ,France ,MESH: Female ,MESH : Registries - Abstract
International audience; BACKGROUND: In France, cancer incidence figures are produced by cancer registries covering only 13.5% to 16% of the whole population of the country. Thus, to produce national figures, estimates have to be computed. Registration disparities between registries concerning tumors of the Central Nervous System (CNS) could have biased these estimates. METHODS: National estimates are based on modelling of the incidence/mortality ratio. The most recent estimations for year 2000 were calculated by the French Cancer Registry Network (FRANCIM) and the department of biostatistics of Lyon University Hospital. Since benign tumors are not recorded in some cancer registries, a new estimate of the incidence of CNS tumors was produced by estimating the number of benign tumors in these registries. RESULTS: In 2000 in France, the number of estimated cases of CNS tumors was 2697 in men and 2602 in women, with incidence rates (World standard) of 7.4 and 6.4 per 100,000 respectively. The incidence increased between 1978 and 2000, on an average by 2.25% per year in men and 3.01% per year in women. However, these estimates do not provide a correct picture of CNS incidence. First of all, pathological diagnoses are not performed in 3.5%-27.5% of the patients with CNS tumors registered in French registries. Second, figures for benign tumors (mainly meningiomas) were provided by only two of nine cancer registries. If benign tumors had been registered by all cancer registries, computed incidence would have increased by 12% for men and 26% for women. CONCLUSION: Incidence of CNS tumors is increasing in France, as in many other countries. To improve comparability with other countries, French cancer registries should also collect data on benign tumors. The discrepancies observed between registries in the proportion of patients without information on histology show differences in diagnostic practices and should be the starting point for a survey on this topic.
- Published
- 2006
7. Incidence of and survival from Wilms' tumour in adults in Europe: data from the EUROCARE study
- Author
-
Mitry , Emmanuel, Ciccolallo , Laura, Coleman , Michel P, Gatta , Gemma, Pritchard-Jones , Kathy, Renseigné , Non, Danzon , Arlette, Evaluative Epidemiology Unit, Fondazione IRCCS, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)
- Subjects
Male ,Cancer Research ,Pediatrics ,MESH: Registries ,030232 urology & nephrology ,MESH : Aged ,[ SDV.CAN ] Life Sciences [q-bio]/Cancer ,MESH: Aged, 80 and over ,0302 clinical medicine ,Epidemiology ,Medicine ,MESH : Female ,Registries ,MESH: Incidence ,Aged, 80 and over ,MESH: Aged ,MESH: Middle Aged ,Relative survival ,Incidence ,Incidence (epidemiology) ,Middle Aged ,MESH : Adult ,Kidney Neoplasms ,MESH : Incidence ,3. Good health ,Europe ,Oncology ,MESH: Survival Analysis ,030220 oncology & carcinogenesis ,Female ,Adult ,medicine.medical_specialty ,Adolescent ,Wilms tumour ,MESH : Male ,MESH: Wilms Tumor ,MESH : Europe ,MESH : Wilms Tumor ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Wilms Tumor ,03 medical and health sciences ,MESH : Adolescent ,Humans ,MESH : Middle Aged ,MESH : Aged, 80 and over ,Aged ,MESH: Adolescent ,MESH: Humans ,business.industry ,MESH : Humans ,Cancer ,MESH: Adult ,Wilms' tumor ,medicine.disease ,Survival Analysis ,MESH: Male ,Confidence interval ,MESH : Kidney Neoplasms ,Wilms' tumour incidence - Wilms' tumour survival - adults ,MESH: Europe ,MESH: Kidney Neoplasms ,MESH : Survival Analysis ,business ,MESH: Female ,MESH : Registries ,Kidney disease - Abstract
International audience; Wilms' tumour, or nephroblastoma, is an embryonal cancer of the kidney that occurs mainly in young children. This is a very rare tumour among adults, with an incidence rate of less than 0.2 per million per year. The aims of this study were to report the survival of adults diagnosed with nephroblastoma in Europe and to analyse time trends and geographic variations in survival. All the adults (age range 15-99 years) diagnosed with a Wilms' tumour during 1983-1994 and registered by one of the 22 cancer registries in 16 countries contributing to the EUROCARE (European cancer registries study on cancer patients' survival and care) database were analysed. Relative survival at 1 and 5 years after diagnosis was estimated by age, sex, geographic area, period of diagnosis and tumour stage. A total of 143 patients, with a median age of 34 years, were included in the analysis. Crude annual incidence rates varied geographically between 0.17 and 0.27 per million. Overall relative survival was 69.9% (95% confidence interval (CI) 61.8-78.0%) at 1 year and 47.3% (38.2-56.4%) at 5 years. Survival was 2.1-fold higher for women than for men (95% CI 1.3-3.5). There was a non-significant trend for better survival for younger patients and localised tumours, but no improvement in survival by period of diagnosis. Survival was not different between geographic areas. Our results suggest a poorer outcome of nephroblastoma in adults compared with published results in children. This may, at least partly, be explained by the rarity of this diagnosis. Prognosis may be improved by the use of specific treatment guidelines for nephroblastoma in adults.
- Published
- 2006
8. Cancer prevalence in France: Time trend, situation in 2002 and extrapolation to 2012
- Author
-
Colonna, Marc, Danzon, Arlette, Delafosse, Patricia, Mitton, Nicolas, Bara, Simona, Bouvier, Anne-Marie, Ganry, Olivier, Guizard, Anne-Valérie, Launoy, Guy, Molinie, Florence, Sauleau, Erik-André, Schvartz, Claire, Velten, Michel, Grosclaude, Pascale, and Tretarre, Brigitte
- Subjects
- *
CANCER patients , *PROSTATE cancer , *CANCER in women , *BREAST cancer - Abstract
Abstract: Background: Cancer prevalence is a basic indicator of the cancer burden in a population and essential to estimate the resources needed for care of cancer patients. This paper provides a prevalence estimate for 2002 and 2012 in France and an assessment of the trend in prevalence over the period 1993–2002. Method: Incidence and survival data from French cancer registries were used to estimate specific 5-year partial prevalence rates that were then applied to the whole French population. Results: In 2002, the 5-year partial prevalence was over 427,000 in men and 409,000 in women. The most frequent cancer site among men was prostate (35% of the cases) and breast in women (45% of the cases). In 2002, in France, more than 3.5% of men over 74 years old are alive with a prostatic cancer diagnosed within 5 years. The increase in the number of cases between 1993 and 2002 was about 40% and was mainly due to prostate and breast cancers. The demographic variations alone induce an increase of the number of prevalent cases of 75,000 among men and 54,500 among women if both incidence and survival are considered as stable during the period 2002–2012. Conclusion: This study uses a large amount of information from cancer registries which makes it possible to assess the cancer burden. Five-year prevalence is very sensitive to changes in incidence and demographic changes. Prevalence has to be estimated regularly in order to ensure accurate medical care meets demand. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
9. Cancer incidence estimation at a district level without a national registry: A validation study for 24 cancer sites using French health insurance and registry data.
- Author
-
Uhry, Zoé, Remontet, Laurent, Colonna, Marc, Belot, Aurélien, Grosclaude, Pascale, Mitton, Nicolas, Delacour-Billon, Solenne, Gentil, Julie, Boussac-Zarebska, Marjorie, Bossard, Nadine, Danzon, Arlette, Altana, Michelle, Frete, François, Weill, Alain, and Rogel, Agnès
- Subjects
- *
CANCER , *HEALTH insurance , *HOSPITAL admission & discharge , *DATA - Abstract
Background: District-level cancer incidence estimation is an important issue in countries without a national cancer registry. This study aims to both evaluate the validity of district-level estimations in France for 24 cancer sites, using health insurance data (ALD demands - Affection de Longue Durée) and to provide estimations when considered valid. Incidence is estimated at a district-level by applying the ratio between the number of first ALD demands and incident cases (ALD/I ratio), observed in those districts with cancer registries, to the number of first ALD demands available in all districts. These district-level estimations are valid if the ratio does not vary greatly across the districts or if variations remain moderate compared with variations in incidence rates. Methods: Validation was performed in the districts covered by cancer registries over the period 2000-2005. The district variability of the ALD/I ratio was studied, adjusted for age (mixed-effects Poisson model), and compared with the district variability in incidence rate. The epidemiological context is also considered in addition to statistical analyses. Results: District-level estimation using the ALD/I ratio was considered valid for eight cancer sites out of the 24 studied (lip-oral cavity-pharynx, oesophagus, stomach, colon-rectum, lung, breast, ovary and testis) and incidence maps were provided for these cancer sites. Conclusion: Estimating cancer incidence at a sub-national level remains a difficult task without a national registry and there are few studies on this topic. Our validation approach may be applied in other countries, using health insurance or hospital discharge data as correlate of incidence. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
10. Trends in invasive breast cancer incidence among French women not exposed to organized mammography screening: An age-period-cohort analysis
- Author
-
Viel, Jean-François, Rymzhanova, Raouchan, Fournier, Evelyne, and Danzon, Arlette
- Subjects
- *
BREAST cancer , *MAMMOGRAMS , *COHORT analysis , *HORMONE therapy , *POISSON distribution , *CANCER invasiveness , *DISEASES in women - Abstract
Abstract: Background: The long tenure of the Doubs cancer registry (France) and the late implementation of a mass screening program provide a unique opportunity to assess the relative contributions of age, period and cohort effects to the increase in female invasive breast cancer incidence, while avoiding the influence of an organized screening program. Methods: Population and incidence data were provided for the Doubs region during the 1978–2003 period. Breast cancer counts and person-years were tabulated into 1-year classes by age and time period. Age-period-cohort models with parametric smooth functions were fitted to the data, assuming a Poisson distribution for the number of observed cases. Results: A total of 5688 incident cases of invasive breast cancer in women were diagnosed in women aged 30–84 years in the Doubs region between 1978 and 2003. The annual percentage increase in incidence is 2.09%. Age effects rise dramatically until age 50, and at a slower pace afterwards. Large cohort curvature effects (p <10−6), show departure from linear trends, with a significant peak for women born around 1940. Period curvature effects are lower in magnitude (p =0.01). Conclusion: Both cohort and period effects are involved in the marked increase in breast cancer incidence over a 25-year period in the Doubs region. Although the future trend for breast cancer incidence is difficult to predict, the introduction of an organized screening program, and the sharp decline in hormone replacement therapy use will likely contribute to period effects in future analyses. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.